Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001)

European Journal of Cancer

Volumn 38, Issue 11, 2002, Pages 1429-1436

  Van Cutsem, E ^a   Dicato, M ^b   Wils, J ^c   Cunningham, D ^d   Diaz Rubio, E ^e   Glimelius, B ^f   Haller, D ^g   Johnston, P ^h   Kerr, D ⁱ   Koehne, C H ^j   Labianca, R ^k   Minsky, B ^l   Nordlinger, B ^m   Roth, A ⁿ   Rougier, P ^m   Schmoll, H J ^o  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Centre Hospitalier de Luxembourg   (Belgium)

^c LAURENTIUS HOSPITAL   (Netherlands)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^k OSPEDALI RIUNITI   (Italy)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m Service d'Hépatogastroentérologie et Oncologie Digestive   (France)

ⁿ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^o MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

more..

Author keywords

Adjuvant chemotherapy; Adjuvant radiotherapy; Colon cancer; Rectal cancer

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; EDRECOLOMAB; FLUOROURACIL; IRINOTECAN; LEVAMISOLE; LOMUSTINE; MITOMYCIN; OXALIPLATIN; VINCRISTINE SULFATE;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG EFFECT; HUMAN; LAPAROTOMY; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RECTUM CARCINOMA; RECURRENCE RISK; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036313633     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00122-3     Document Type: Article

References (47)

1. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
2. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer
3. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
4. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03
5. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
6. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer
7. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer
8. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: Five-year final report of INT-0089
9. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04
10. Postoperative management of stage II/III colon cancer: A decision analysis
11. Current controversies in cancer. Is there a standard adjuvant treatment for colon cancer?
12. Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives
13. Comparison of fluorouracil with additional levamisole, higher dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: A randomized trial
14. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup study
15. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer
16. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors
17. Developments in fluoropyrimidine therapy for gastrointestinal cancer
18. A systematic overview of chemotherapy effects in colorectal cancer
19. Multicentre randomized trial of protracted venous infusion (PVI) 5 FU compared to 5 FU/folinic acid (5FU/FA) as adjuvant therapy for colorectal cancer
20. Phase III randomized trial of bolus 5-FU/Leucovorin/Levamisole versus 5-FU continuous infusion/levamisole as adjuvant therapy for high risk colon cancer (SWOG 9415/INT-0153)
21. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer
22. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four national surgical adjuvant breast and bowel project adjuvant studies (C-01, C-02, C-03, and C-04)
23. The tea leaves of small trials
24. Defining optimal treatment for stage II colon cancer: Does decision analysis help?
25. Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial
26. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumour cell vaccine: Eastern Cooperative Oncology Group Study E5283
27. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
28. Edrecolomab (17-1A antibody) alone or in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of stage III colon cancer: Results of a phase III study
29. Portal vein chemotherapy for colorectal cancer: A meta-analysis of 4000 patients in 10 studies
30. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: A randomised trial
31. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on liver metastases
32. Results of the Intergroup (Eastern Cooperative Oncology Group (ECOG) and Southwest Oncology Group (SWOG)) prospective randomized study of surgery alone versus continuous hepatic artery infusion of FUDR and continuous systemic infusion of 5FU after hepatic resection for colorectal liver metastases
33. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer
34. Hepatic arterial therapy for the treatment of metastatic colorectal cancer
35. Waiting for the definitive trial of hepatic arterial chemotherapy for colorectal cancer
36. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: Results from NSABP protocol R-01
37. Prolongation of the disease-free interval in surgically treated rectal carcinoma
38. Survival after postoperative combination treatment of rectal cancer
39. Effective surgical adjuvant therapy for high-risk rectal carcinoma
40. Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer
41. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02
42. Chemoradiotherapy for rectal cancer - Is there an optimal combination?
43. Improving adjuvant therapy of rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery
44. Adjuvant and neoadjuvant radiation therapy for rectal cancer
45. Adjuvant radiotherapy for rectal cancer: A systematic overview of 8507 patients from 22 randomized trials
46. Improved survival with preoperative radiotherapy in resectable rectal cancer
47. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer